doi: 10.5114/wo.2018.82642 25 LuCWardPSKapoorGSRohleDTurcanSAbdel-WahabOet al
Follow-Up Appointments Schedule and attend any recommended follow-up appointments or lab tests to monitor your progress and response to the treatment
however, the safety and efficacy of such therapy have not been systematically evaluated Risk factors of statinfibrate-related myopathy include advanced age, female gender, low BMI, renal disease, diabetes mellitus, hypothyroidism, multisystem disease, fever, surgery, trauma, and strenuous physical exercise The likelihood and/or severity of myopathy also depend on pharmacologic properties of the statin and the fibrate, such as their enzymatic metabolism or excretion and/or their protein-regulated intercellular transport Fenofibrate or fenofibric acid may be fibrates of choice for statinfibrate therapy because, according to pharmacokinetic and postmarketing data, they are associated with lower risks of myopathy (versus gemfibrozil) This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access 189,00 per year only 15,75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
The NICE Clinical Knowledge Summary on B12 and folate deficiency recommends assessing the underlying cause before choosing a treatment path, which is why speaking to a pharmacist or GP first matters
In summary, prolotherapy stands as a currently used therapy in the EDS toolkit, particularly suited for hypermobile joints causing chronic pain
Immunity 53 , 496509 (2020)
